BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF
Limited financial coverage for XTEN.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
Under typical conditions, this fund commits at least 80% of its total investment capital (including any borrowed funds) to a portfolio predominantly made up of U. S. Treasury debt instruments.
- IPO
- 2022
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on XTEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.01B
- Div Yield
- 4.62%
- 52W High
- $47.50
- 52W Low
- $41.84
- 50D MA
- $43.73
- 200D MA
- $45.28
- Beta
- 1.58
- RSI (14)
- 35
- Avg Volume
- 309.78K
No earnings-call transcripts are available for XTEN yet.
- Free Float
- 0.0%
- Shares Outstanding
- 23.77M
- Float Shares
- 0
of shares held by institutions
186 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Prime Capital Investment Advisors, LLC | 4.14M | ▲ 2.15M |
| Envestnet Asset Management Inc | 2.57M | ▼ 432.06K |
| Fifth Third Bancorp | 2.25M | ▲ 2.15M |
| Resources Investment Advisors, LLC. | 1.71M | ▲ 172.01K |
| Jpmorgan Chase & Co | 1.24M | ▼ 418.95K |
| Northland Capital Management LLC | 590.57K | ▲ 24.39K |
| Austin Private Wealth, LLC | 499.77K | ▼ 38.69K |
| Virtue Capital Management, LLC | 470.88K | ▼ 131.92K |
| Srs Capital Advisors, Inc. | 435.82K | ▲ 28.37K |
| Cerity Partners LLC | 360.74K | ▼ 164.52K |
| Horst & Graben Wealth Management LLC | 318.30K | ▼ 123.64K |
| Heck Capital Advisors, LLC | 239.99K | ▲ 16.10K |
Held by 1 ETFs
Biggest fund positions in XTEN by dollar value.
Our XTEN coverage
Recent articles, reports, and earnings notes.
No research on XTEN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XTEN report →Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
businesswire.com · Oct 8
Why Investors Are Eyeing Short & Long U.S. Treasury ETFs
etftrends.com · Jul 24
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
businesswire.com · Apr 13
Park Avenue Securities LLC Sells 37,510 Shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN
defenseworld.net · Mar 22
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
businesswire.com · Feb 23
Heck Capital Advisors LLC Has $9.10 Million Stock Holdings in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN
defenseworld.net · Jan 10
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
businesswire.com · Oct 9
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
businesswire.com · Jul 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.